05.09.18: Second quarter of 2018

Bayer completes biggest acquisition in its historyMonsanto business included on prorated basis from June 7 / Group sales advance by 8.5 percent (Fx & portfolio adj.) to 9.481 billion euros / EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effects / Pharmaceuticals registers higher sales (Fx & portfolio adj.) but lower earnings - substantial increase in R&D investment / Consumer Health business weak again / Crop Science achieves strong increase in sales and earnings after weak prior-year quarter / Animal Health improves sales (Fx & portfolio adj.) and earnings / Net income amounts to 799 million euros / Core earnings per share up by 1.3 percent at 1.54 euros / Group outlook for 2018 confirmed, with adjustments to reflect acquisitionmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news